Stockscreener 앱 받기
0.96
6.31%
0.057
전일 마감가:
$0.903
열려 있는:
$0.95
하루 거래량:
11,055
Relative Volume:
0.09
시가총액:
$2.91M
수익:
-
순이익/손실:
$-736.70K
주가수익비율:
-96.00
EPS:
-0.01
순현금흐름:
$-4.14M
1주 성능:
+1.05%
1개월 성능:
-2.02%
6개월 성능:
-37.74%
1년 성능:
-71.56%
1일 변동 폭
$0.91
$0.99
1주일 범위
$0.902
$1.02
52주 변동 폭
$0.82
$3.92
Xortx Therapeutics Inc Stock (XRTX) Company Profile
XRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.96 | 2.91M | 0 | -736.70K | -4.14M | -0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Xortx Therapeutics Inc 주식(XRTX)의 최신 뉴스
XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks
XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks
XORTX Announces Update for Discussion with the FDA - GlobeNewswire
XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks
XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com
XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com
XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan
Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News
XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks
XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire
Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com
XORTX to Present at Microcap Conference - GlobeNewswire
XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks
Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan
XORTX Therapeutics Announces Auditor Transition - MSN
XORTX Announces Change of Auditor - TipRanks
XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks
XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan
XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel
Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel
XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks
XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire
XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan
XORTX appoints finance veteran as its new CFO - MSN
XORTX Therapeutics Welcomes New CFO Dr. Bumby - TipRanks
XORTX Strengthens Executive Team - The Manila Times
XORTX Therapeutics Taps Former Eli Lilly Veteran Dr. Michael Bumby as New CFO - StockTitan
XORTX Therapeutics Unveils New Kidney Disease Discoveries - TipRanks
XORTX Announces Presentation at the Rare and Genetic Disease Summit - GlobeNewswire
XORTX Therapeutics Unveils Breakthrough ADPKD Research: Genetic Factors Key to Disease Progression - StockTitan
XORTX Therapeutics Inc. Faces Financial Challenges - TipRanks
XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 - sharewise
XORTX Highlights Kidney Disease Study at ASN - TipRanks
XORTX Secures $1.5 Million in Latest Offering - TipRanks
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
Xortx Therapeutics Inc (XRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):